Upregulation of LncRNA BCYRN1 promotes tumor progression and enhances EpCAM expression in gastric carcinoma
PDF | HTML | How to cite
Metrics: PDF 1765 views | HTML 2314 views | ?
Hao Ren1,2, Xiaomin Yang3, Yongmei Yang1, Xiaoyu Zhang4, Rui Zhao1, Ran Wei5, Xin Zhang1, Yi Zhang1
1Department of Clinical Laboratory, Qilu Hospital, Shandong University, Jinan, Shandong Province, China
2Department of Laboratory, Yuhuangding Hospital, Qingdao University Medical College, Yantai, Shandong Province, China
3Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong Province, China
4Clinical Medicine of Undergraduate, Taishan Medical University, Taian, Shandong Province, China
5Wakayama Medical University, Wakayama, Wakayama, Japan
Yi Zhang, email: [email protected]
Keywords: BCYRN1; lncRNA; gastric carcinoma; tumor progression; EpCAM
Received: June 09, 2017 Accepted: December 13, 2017 Published: December 21, 2017
Brain cytoplasmic RNA 1 (BCYRN1), along non-coding RNA, plays a critical role in various diseases, including some cancers. However, the expression of BCYRN1 and its roles in gastric carcinoma (GC) still remain unidentified. Thus, this study employed RT-qPCR to detect expression of BCYRN1 in 85 paired GC samples and adjacent normal tissues, and performed in vitro studies to explore effects of BCYRN1 in GC cells on cell proliferation, apoptosis and migration. We found BCYRN1 was significantly upregulated in GC samples, and its expression was positively correlated with advanced TNM stage (p = 0.0012) and tumor size (p = 0.027). Functionally, BCYRN1 knockdown by siRNA could inhibit cell proliferation, induce G1/G0 cell cycle arrest, increase apoptosis and impair migratory ability of AGS cells. Moreover, the results of RT-qPCR and western blotting indicated that knockdown of BCYRN1 notably decreased the expression of epithelial cell adhesion molecules (EpCAM). Otherwise, overexpression of BCYRN1 in GC cells (BGC-823 and SGC-7901) could reverse the effects of BCYRN1 knockdown. Taken together, our data indicate for the first time that BCYRN1 acts as an oncogenic lncRNA in GC progression and may be a potential therapeutic target in GC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.